# A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer

> **NCT01541007** · PHASE2 · COMPLETED · sponsor: **Jeffrey Yachnin M.D., PhD.** · enrollment: 100 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel
- **DRUG:** weekly cabazitaxel

## Key facts

- **NCT ID:** NCT01541007
- **Lead sponsor:** Jeffrey Yachnin M.D., PhD.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2015-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01541007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01541007, "A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01541007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*